Research and Practice in Thrombosis and Haemostasis

Papers
(The H4-Index of Research and Practice in Thrombosis and Haemostasis is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Prothrombotic changes in patients with COVID‐19 are associated with disease severity and mortality70
Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)58
Sexism in the management of bleeding disorders57
Tranexamic acid evidence and controversies: An illustrated review56
The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study49
Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients48
Comparison of the coagulopathies associated with COVID‐19 and sepsis41
Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis39
Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries36
The role of platelets in sepsis35
Validation of the IMPROVE‐DD risk assessment model for venous thromboembolism among hospitalized patients with COVID‐1935
Abstract35
Protease‐activated receptors: An illustrated review35
Abstracts33
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)32
Hormonal therapies and venous thrombosis: Considerations for prevention and management31
The psychological impact of pulmonary embolism: A mixed‐methods study30
Blood clot contraction: Mechanisms, pathophysiology, and disease28
Visualizing thrombosis to improve thrombus resolution26
Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set25
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE25
Impact of novel hemophilia therapies around the world25
Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants25
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment24
0.058137178421021